Takeda Reports Results of TAK-003 in P-III TIDES (DEN-301) Trial for Dengue

 Takeda Reports Results of TAK-003 in P-III TIDES (DEN-301) Trial for Dengue

Takeda Reports Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks

Shots:

  • The P-III TIDES study contains three parts assessing TAK-003 (0.5ml, SC) vs PBO in patients for the prevention of dengue fever of any severity and due to any of the four dengue virus serotypes in children and adolescents, evaluating the efficacy, safety and immunogenicity
  • The P-III study demonstrated well-tolerated, safe and efficacious results in preventing fever till date and is being continued with expected results in H2’19
  • Takeda’ TAK-003 is a tetravalent live-attenuated dengue serotype 2 virus and has shown safe and well-tolerated results in P-I/II study for children and adolescent

Click here to read full press release/ article | Ref: Takeda| Image: The Boston Globe

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post